
Is VUG a Good ETF to Buy?
For the last few years, earnings growth from the tech…
Trailing 12 Months | Fiscal Quarters | |||||
---|---|---|---|---|---|---|
Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
Income Statement | ||||||
Revenue | $284.4M | $322.4M | $313.9M | $76.3M | $49M | |
Gross Profit | $223.4M | $252.7M | $239.6M | $60.7M | $31.6M | |
Operating Income | $43.8M | $28.1M | -$12.6M | $10.4M | -$27.9M | |
EBITDA | $48.3M | $33.2M | -$5.7M | $11.6M | -$25.5M | |
Diluted EPS | $0.78 | $0.43 | -$0.41 | $0.16 | -$0.69 |
Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
---|---|---|---|---|---|---|
Balance Sheet | ||||||
Current Assets | $216.4M | $271.4M | $311.7M | $365.3M | $367.9M | |
Total Assets | $257.4M | $345.8M | $418.8M | $488.7M | $509.5M | |
Current Liabilities | $41.2M | $48.8M | $51.7M | $65M | $70.3M | |
Total Liabilities | $60.2M | $87.2M | $82.7M | $102.7M | $112.2M | |
Total Equity | $197.2M | $258.6M | $336.1M | $386M | $397.3M | |
Total Debt | $1.4M | -- | -- | -- | -- |
Trailing 12 Months | Fiscal Quarters | |||||
---|---|---|---|---|---|---|
Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
Cash Flow Statement | ||||||
Cash Flow Operations | $35.7M | $14.6M | $15.7M | $32M | $642K | |
Cash From Investing | -$156.4M | $74.3M | -$59.2M | $22.4M | -$19.5M | |
Cash From Financing | $8.3M | $7.4M | $5.7M | $367K | -$110K | |
Free Cash Flow | $17.6M | -$3.6M | -$7.7M | $28.9M | -$5.1M |
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of its sales are generated from the ophthalmic surgical product segment.
In the current month, STAA has received 3 Buy ratings 9 Hold ratings, and 1 Sell ratings. The STAA average analyst price target in the past 3 months is $18.67.
According to analysts, the consensus estimate is that Staar Surgical share price will rise to $18.67 per share over the next 12 months.
Analysts are divided on their view about Staar Surgical share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Staar Surgical is a Sell and believe this share price will drop from its current level to $13.00.
The price target for Staar Surgical over the next 1-year time period is forecast to be $18.67 according to 13 Wall Street analysts, 3 of them rate the stock a Buy, 1 rates the stock a Sell, and 9 analysts rate the stock a Hold.
According to Wall Street analysts, the consensus rating for Staar Surgical is a Hold. 9 of 13 analysts rate the stock a Hold at this time.
You can purchase shares of Staar Surgical via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Staar Surgical shares.
Staar Surgical was last trading at $18.01 per share. This represents the most recent stock quote for Staar Surgical. Yesterday, Staar Surgical closed at $18.33 per share.
In order to purchase Staar Surgical stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Signup to receive the latest stock alerts
For the last few years, earnings growth from the tech…
Intel Corporation (NASDAQ:INTC)’s recent innovations, Xeon 6 SoC and Xeon®…
For many years, Walmart (NYSE:WMT) has been the world’s largest…
Market Cap: $3.3T
P/E Ratio: 36x
Market Cap: $2.8T
P/E Ratio: 32x
Market Cap: $2.7T
P/E Ratio: 37x
Guardant Health [GH] is up 1.1% over the past day.
Teradyne [TER] is down 0.36% over the past day.
Limbach Holdings [LMB] is down 4.39% over the past day.